protein tyrosine phosphatases

(redirected from Protein tyrosine phosphatase)
Also found in: Acronyms, Wikipedia.

protein tyrosine phosphatases

A family of phosphate hydrolyzing enzymes that help regulate signaling between cells. Some diseases linked to abnormalities in protein tyrosine phosphatases include allergies, asthma, diabetes mellitus, obesity, and Alzheimer's disease.
References in periodicals archive ?
Protein tyrosine phosphatases play an integral role within the insulin signaling cascade by negatively regulating signal transduction.
Single nucleotide polymorphism in protein tyrosine phosphatase PTP-1B is associated with protection from diabetes or impaired glucose tolerance.
Tyrogene's second technology platform offers the ability to rapidly identify and validate additional protein tyrosine phosphatase targets.
About CEPTYR: CEPTYR is a private biopharmaceutical company and a world leader in the field of protein tyrosine phosphatase enzymes (PTPs).
The role for protein tyrosine phosphatase nonreceptor type 2 in regulating autophagosome formation
AKB-9778, a first-in-class human protein tyrosine phosphatase beta (HPTP) inhibitor, works to activate Tie2, a receptor on vascular endothelial cells that promotes vascular stability, preventing abnormal blood vessel growth and vascular leak.
AKB-9778 works by inhibiting the Human Protein Tyrosine Phosphatase (HPTP) enzyme which acts as a negative regulator of the Tie-2 receptor.
a small molecule discovery and development company focused on anemia and vascular disorders, today announced that it has dosed the first subjects in a first-in-man Phase 1 study of AKB-9778, a first-in-class human protein tyrosine phosphatase beta (HPTP) inhibitor in development for diabetic macular edema (DME) and diabetic retinopathy (DR).
The paper, "Targeting protein tyrosine phosphatase after myocardial infarction restores cardiac sympathetic innervation and prevents arrhythmias," has implications for patients who survive a heart attack, and remain at risk for severe cardiac arrhythmias and sudden cardiac death.
VioQuest Pharmaceuticals licensed rights to sodium stibogluconate from the Cleveland Clinic Foundation and is developing the drug as a protein tyrosine phosphatase inhibitor for a range of potential indications.
Receptor signaling protein tyrosine phosphatase activity
The abstract from the Lenocta study, entitled "Phase I dose-escalation study of sodium stibogluconate (SSG), a protein tyrosine phosphatase inhibitor, combined with interferon-alpha for patients with solid tumors" (abstract #3011), is available on the ASCO website at www.

Full browser ?